桂龙咳喘宁品牌怎么样 申请店铺

我要投票 桂龙咳喘宁在医疗器械行业中的票数:37 更新时间:2024-12-23
桂龙咳喘宁是哪个国家的品牌?「桂龙咳喘宁」是桂龙药业(安徽)有限公司旗下著名品牌。该品牌发源于安徽省马鞍山市,由创始人Stephen John Coplin在2003-11-25期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
桂龙咳喘宁怎么样

桂龙咳喘宁,知名咳嗽药品牌,成立于1989年,高新技术企业,中药呼吸系统和咽喉品类领域领先企业,集研发/生产/销售于一体的中药企业


桂龙药业成立于1989年,是集研发、生产、销售为一体的中药行业企业。桂龙,取自谐音“贵”“隆”,意为富贵华荣兴旺发达。且“桂”,有桂树四季翠绿,香飘万里而古朴典雅,是传统中药的化身;“龙”,象征着东方文化与蓄势勃发的力量。

公司拥有员工约1000人,总部位于福建省厦门市,在安徽省马鞍山市和山西省忻州市设有两个生产基地,总占地面积11万平方米,建筑面积近4万平方米,均为现代化的花园式GMP工厂。 桂龙药业在全国设立27个销售办事处,拥有500人的销售团队,销售人员有效管理近6万家零售终端门店,产品覆盖全国近三十万家零售药店,以及全国所有主流连锁药店。

2003年经当涂县委、县人大招商引资在当涂经济开发区征地120亩,投资5000万元,建立了一座符合GMP要求的生产企业——桂龙药业(安徽)有限公司。公司目前拥有国药准字号品种31个,主要生产经营范围为:片剂、胶囊剂、颗粒剂、煎膏剂、及生产加工、经营糖果。其主导产品主要有:慢严舒柠牌清喉利咽颗粒、桂龙咳喘宁胶囊、新生化颗粒、复方柴胡安神颗粒、好爽糖等。科技创新、管理创新、岗位创新、市场创新是企业发展的原动力。科技人员占员工比例36%以上。公司拥有的技术研发中心和检测中心,保障了公司科技的可持续发展,保障了药品的质量和药品的安全。

桂龙专注于中药呼吸系统和咽喉品类领域,创立了国内呼吸系统和咽喉领域两个品牌“桂龙”牌、“慢严舒柠”牌。

“有健康就有桂龙,桂龙药业、健康事业”是桂龙药业的宗旨;品牌战略、人才战略、创新战略是桂龙发展的三个支撑;“敬业”、“诚信”、“责任”、“创新”是桂龙发展的核心理念。随着企业的发展壮大,桂龙药业现有的生产与研发平台不足以支撑桂龙药业未来若干年的迅速持续发展,为此桂龙药业决定在当涂经开区征地数百亩,以国内专业的制药技术和工艺装备,打造一个集生物医药生产和研究开发于一体的现代化医药产业园,以此支撑桂龙未来十多年的长足发展和技术创新、科技进步。


Guilong Kechuanning, a famous cough medicine brand, was founded in 1989. It is a high-tech enterprise, a leading enterprise in the field of traditional Chinese medicine respiratory system and throat category. Guilong pharmaceutical, a traditional Chinese medicine enterprise integrating R & D, production and sales, was founded in 1989. It is a traditional Chinese Medicine enterprise integrating R & D, production and sales. Guilong, from the homonym "Gui" and "long", means prosperity and prosperity. And "Gui" is the embodiment of traditional Chinese medicine, which has four seasons of green, fragrant and elegant, and "long" symbolizes the power of Oriental culture and vigorous development. The company has about 1000 employees and its headquarter is located in Xiamen City, Fujian Province. It has two production bases in Maanshan City, Anhui Province and Xinzhou City, Shanxi Province, covering a total area of 110000 square meters and a building area of nearly 40000 square meters, all of which are modern garden GMP factories. Guilong pharmaceutical has 27 sales offices in China, with a sales team of 500 people. The sales staff effectively manage nearly 60000 retail terminal stores, covering nearly 300000 retail pharmacies and all mainstream chain pharmacies in China. In 2003, Dangtu County Party committee and County People's Congress invested 120 mu of land in Dangtu economic development zone and invested 50 million yuan to establish a GMP compliant production enterprise - Guilong Pharmaceutical (Anhui) Co., Ltd. At present, the company has 31 varieties of State Pharmaceutical quasi brand, the main production and business scope are: tablets, capsules, granules, decoctions, as well as the production, processing and operation of candy. Its main products are: Manyan shuning brand Qinghou Liyan granules, Guilong Kechuanning capsule, xinbiochemical granules, compound Bupleurum Anshen granules, haoshuangtang, etc. Technological innovation, management innovation, post innovation and market innovation are the driving force of enterprise development. Science and technology personnel account for more than 36% of employees. The technology R & D center and testing center of the company ensure the sustainable development of the company's science and technology and the quality and safety of drugs. Focusing on the field of respiratory system and throat category of traditional Chinese medicine, Guilong has established two domestic brands in the field of respiratory system and throat, "Guilong" brand and "slow, strict, shuning" brand. The aim of Guilong pharmaceutical industry is to "have health, Guilong pharmaceutical industry and health cause"; brand strategy, talent strategy and innovation strategy are the three supports for the development of Guilong; dedication, integrity, responsibility and innovation are the core concepts for the development of Guilong. With the development of enterprises, the existing production and R & D platform of Guilong pharmaceutical industry is not enough to support the rapid and sustainable development of Guilong pharmaceutical industry in the next few years. Therefore, Guilong pharmaceutical industry decided to take hundreds of mu of land in Dangtu Economic Development Zone to build a modern pharmaceutical industrial park integrating biological pharmaceutical production and research and development with domestic professional pharmaceutical technology and process equipment, so as to support Guilong pharmaceutical industry Long's considerable development and technological innovation and scientific and technological progress in the next ten years.

本文链接: https://brand.waitui.com/0d765d197.html 联系电话:05556758271

千城特选小程序码

7×24h 快讯

湖畔实验室发布2024年创新成果

36氪获悉,12月22日,湖畔实验室(数据科学与应用浙江省实验室)发布包括AI多癌早筛、气象大模型等在内的多项年度创新成果。实验室用前沿AI技术迎战医疗、能源、农业、集成电路等产业难题,部分成果达到国际领先水平,并实现快速的落地应用,构建起“科技+产业”的正循环。作为浙江由民企牵头建设的省实验室,湖畔实验室成立于2020年7月,依托阿里巴巴达摩院建设,聚焦数据科学与应用领域。大会上,湖畔实验室进行了年度教科人一体化优秀项目颁奖和国家级博士后工作站揭牌,并与杭州电子科技大学战略合作签约。

2小时前

卡塔尔警告欧盟,欧盟新指令或致卡方停止向欧盟输送天然气

12月22日,卡塔尔能源事务国务大臣、卡塔尔能源公司总裁兼首席执行官萨阿德·卡比警告,欧盟新指令或导致卡塔尔停止向欧盟输送天然气。卡比说,如果欧盟实施《企业可持续发展尽职调查指令》,让卡塔尔能源公司损失5%的收入,那卡方宁愿不进入欧洲市场。他强调,他不是在虚张声势,因为卡塔尔能源公司的收入属于卡塔尔政府和人民,没有人会接受损失这么多资金。卡比称,欧盟应该对《企业可持续发展尽职调查指令》进行审查。欧盟理事会今年5月批准通过《企业可持续发展尽职调查指令》。该指令将在未来几年分阶段实施,对在欧盟运营的具有一定规模的企业引入强制性的环境尽职调查要求,旨在减轻或终止对环境造成的不利影响。对于违反该指令的企业,最高可被处以全球营业额5%的罚款。

2小时前

上海地铁:经全力抢修,11号线受损区段预计今晚21时左右恢复开通运营

12月22日晚间,上海申通地铁集团有限公司运营管理中心发布消息:经全力抢修,11号线受损区段预计今(12月22日)晚21时左右恢复开通运营,感谢您的配合! ​​​ 22日8时许,上海地铁11号线马陆至武威路站区间,由于外部一施工工地履带吊车倒塌侵入,造成地铁线路设备和一列正常运行的地铁局部受损,未造成人员伤亡。

2小时前

国泰集团行政总裁林绍波:希望明年航点数量增至超过100个

12月22日消息,国泰集团行政总裁林绍波表示,国泰无论在香港、内地或国际都有身份危机,他强调国泰的定位很清楚,与香港定位一致,就是“植根香港,背靠祖国,联通世界”;疫情3年是国泰航空78年历史中最困难的时期,期间国泰航班曾跌出全球十大最佳航空公司。他希望明年可超越疫情前水平,将航点数量增至超过100个,而国泰的目标是成为全球最佳航空公司。(香港电台网)

2小时前

鸿蒙智行泊车代驾VPD开启全量推送

据华为终端消息,鸿蒙智行泊车代驾VPD开启全量推送。

2小时前

本页详细列出关于尼德克NIDEK的品牌信息,含品牌所属公司介绍,尼德克NIDEK所处行业的品牌地位及优势。
咨询